TrialClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2022

Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations.

Payam Tabarsi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.